Trippa, Lorenzo

Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape

Marco, E., Karp, R. L., Guo, G., Robson, P., Hart, A. H., Trippa, L., & Yuan, G.-C. (2014) · Proceedings of the National Academy of Sciences

Single-cell and spatial transcriptomicsGene Regulatory Network Analysis

Cited by 268

Prognostic role of circulating exosomal miRNAs in multiple myeloma

Manier, S., Liu, C.-J., Avet-Loiseau, H., Park, J., Shi, J., Campigotto, F., Salem, K. Z., Huynh, D., Glavey, S. V., Rivotto, B., et al. (2017) · Blood

Extracellular vesicles in diseaseMultiple Myeloma Research and Treatments

Cited by 266

Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression

Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 187

Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study

El-Khoury, H., Lee, D. J., Alberge, J.-B., Redd, R., Cea-Curry, C. J., Perry, J., Barr, H., Murphy, C., Sakrikar, D., Barnidge, D., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 94

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

Cowan, A., Ferrari, F., Freeman, S. S., Redd, R., El-Khoury, H., Perry, J., Patel, V., Kaur, P., Barr, H., Lee, D. J., et al. (2023) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 86

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 70

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Nadeem, O., Magidson, S., Midha, S., O'Donnell, E. K., Hartley-Brown, M. A., Sperling, A. S., Redd, R. A., Marto, M., Davie, C., Ricciardi, C., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 37

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Bustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 35

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 20